Takeaways
#- Strazza had bought 10x Genomics the previous day. He favored its reversal pattern above $54 after the stock’s trading range tightened.
- CRISPR Therapeutics was still well below the old high and anchored VWAP he wanted it to recover.
- A weekly retest supported Strazza’s $257 Wingstop objective. For Spotify, a base near $160 still lacked the momentum he wanted in a breakout.
Steve Strazza liked genomics stocks enough to have bought one the previous day. It wasn't the one a viewer asked him about. On the June 29, 2023 edition of Chart Request Live, he and Spencer Israel compared CRISPR Therapeutics, still trading in the $50s, with the setup he had bought in 10x Genomics.
Strazza started with the ARK Genomic Revolution ETF. It was moving sideways, and CRISPR Therapeutics looked much the same. The level he wanted the stock to reclaim sat near its previous summer high and an anchored volume-weighted average price, the average price of trades since a chosen date, weighted by volume. CRISPR was a long way from that area. He said he would get interested again in the $80s.
10x Genomics had been trading in progressively narrower ranges since January. The swings had tightened again in April. Strazza expected a larger move to follow, but the squeeze alone couldn't tell him which way. Price supplied the other piece: above $54, he thought the pattern favored a reversal higher. He had bought the stock the day before the broadcast.
A weekly chart for the idea, a daily chart for the entry
Another viewer did Strazza a favor by asking specifically for a weekly chart of Wingstop. He could answer the question about the trend first. The restaurant stock had risen for years, broken above a previous ceiling and come back to test it. On that longer view he saw room for a move toward $257.
A weekly chart didn't give him a particularly precise entry. For that he switched to daily prices and described anchoring a volume-weighted average to the stock’s highs. The old ceiling had held on the retest; the shorter chart gave him a way to judge when buyers were taking control again. With 10x he already had a position. With Wingstop he was walking the viewer through how he would look for one.
What Spotify still lacked at $160
Spotify had something else Strazza liked: a base with a 200-day moving average that was flattening and beginning to turn up. A peak from March of the previous year put a useful reference near $160, right where the stock had begun to coil.
Then he checked momentum. Since February, the price had climbed without momentum reaching the overbought zone. Strazza wanted the opposite of what that word might suggest. If Spotify was strong enough to break out to a fresh 52-week high, he wanted to see buying strong enough to produce an overbought reading as well. Until that happened, he had a price worth watching and a reason to question the breakout.
Questions and answers
#Questions answered in the original 2023-06-29 episode.
Why did Strazza favor 10x Genomics over CRISPR Therapeutics in June 2023?
10x had coiled for months and held above his $54 reference. CRISPR remained in a range, trading in the $50s while his area of interest was up in the $80s.
Why did Strazza want an overbought reading in Spotify?
Momentum had failed to reach that range since February even as price rose. He wanted stronger buying to accompany an attempt at a 52-week high.
Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .